Nuclidium Company
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
Employee Number:
11-50
Headquarters:
Basel, Basel-Stadt, Switzerland, Europe
Founded Date:
2018-01-01
Industry:
Biomarkers & Liquid Biopsy
Super Industry:
Diagnostics & Genomics
Phone Number:
+41 78 326 6666
Investors:
Eurazeo, European Innovation Council, European Investment Bank, Highlight Capital, NRW.BANK
Ipo Status:
private
City:
Basel
Region:
Basel-Stadt
Country:
Switzerland
Founders:
Gustav Schulthess, Leila Jaafar-Thiel